PREFERRED MEDICATIONS:
- generic ketorolac 0.5% or 0.4% ophthalmic solution
- generic bromfenac 0.09% ophthalmic solution
- generic diclofenac 0.1% ophthalmic solution
- generic flurbiprofen 0.03% ophthalmic solution
- Ilevro® (nepafenac 0.3% ophthalmic suspension – Alcon)
- Nevanac® (nepafenac 0.1% ophthalmic suspension – Alcon)
- Prolensa™ (bromfenac 0.07% ophthalmic solution – Bausch & Lomb)

NON-PREFERRED MEDICATIONS:
- Acular® (ketorolac tromethamine 0.5% ophthalmic solution – Allergan)
- Acular LS® (ketorolac tromethamine 0.4% ophthalmic solution – Allergan)
- Acuvail® (ketorolac tromethamine 0.45% ophthalmic solution – Allergan)

OVERVIEW
Numerous brand and generic ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) are currently available. The ophthalmic NSAIDs are indicated for the management of ocular pain and inflammation in the postoperative setting. Ketorolac 0.5% ophthalmic solution is also indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis (SAC). Of the currently available ophthalmic NSAIDs used in an outpatient setting, Nevanac and Ilevro are unique in that they are the only NSAID prodrug formulations. Nepafenac, the active ingredient in Nevanac and Ilevro, is converted to the primary active NSAID agent, amfenac, by ocular tissue hydrolases after nepafenac penetration of the cornea. The clinical significance of this is not known at this time. Bromfenac 0.09% ophthalmic solution, Ilevro, and Prolensa are dosed once daily (QD); the other agents are dosed two times daily (Acuvail), three times daily (Nevanac), or four times daily (ketorolac 0.4%, ketorolac 0.5%, and diclofenac 1%). Ilevro and Nevanac are ophthalmic suspensions and must be shaken well before use.

POLICY STATEMENT
A preferred step therapy program has been developed to encourage the use of one Step 1 product prior to the use of a Step 2 product. If the preferred step therapy rule is not met for a Step 2 agent at the point of service, coverage will be determined by the preferred step therapy criteria below. All approvals are provided for 1 year in duration.

Automation: Patients with a history of one Step 1 drug within the 130-day look-back period are excluded from step therapy.
**Step 1:** generic ketorolac 0.5% ophthalmic solution, generic ketorolac 0.4% ophthalmic solution, generic bromfenac 0.09% ophthalmic solution, generic diclofenac 0.1% ophthalmic solution, generic flurbiprofen 0.03% ophthalmic solution, Ilevro, Nevanac, Prolensa

**Step 2:** Acular, Acular LS, Acuvail

**CRITERIA**

1. If the patient has tried one Step 1 product, authorization for a Step 2 product may be given.

**REFERENCES**

7. Bromfenac 0.09% ophthalmic solution [prescribing information]. Weston, FL: Apotex Corp.; February 2014.
8. Diclofenac 0.1% ophthalmic solution [prescribing information]. Tampa, FL: Bausch & Lomb Incorporated; November 2012.